Tofacitinib for the treatment of alopecia areata and variants in adolescents - 18/04/17
, Lucy Y. Liu, BA c, Brett A. King, MD, PhD aAbstract |
Background |
There are no reliably effective therapies for alopecia areata (AA).
Objective |
We sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of adolescent patients with AA.
Methods |
We reviewed the records of 13 adolescent patients with AA treated with tofacitinib. Severity of disease was assessed using the Severity of Alopecia Tool (SALT). Adverse events were evaluated by laboratory monitoring, physical examinations, and review of systems.
Results |
Thirteen patients, aged 12 to 17 years, with AA were treated with tofacitinib. Nine patients experienced clinically significant hair regrowth. Median percent change in SALT score was 93% (mean 61%; 1%-100%) at an average of 6.5 months of treatment. Adverse events were mild.
Limitations |
Limitations include the retrospective nature of the data, small sample size, and lack of a control group.
Conclusion |
Tofacitinib is a promising therapy for AA in adolescents. The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials.
Le texte complet de cet article est disponible en PDF.Key words : adolescent, alopecia areata, Janus kinase, tofacitinib
Abbreviations used : AA, AU, JAK, SALT
Plan
| Supported by the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research (Dr King). |
|
| Disclosure: Dr King has served on advisory boards or is a consultant to Aclaris Therapeutics, Inc., Pfizer, Inc., Eli Lilly and Company, and Concert Pharmaceuticals, Inc. Dr Craiglow and Ms Liu have no conflicts of interest to declare. |
|
| Presented as a poster at the Society for Pediatric Dermatology meeting, Minneapolis, MN, July 14-17, 2016. |
Vol 76 - N° 1
P. 29-32 - janvier 2017 Retour au numéro
Article précédent
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Lucy Y. Liu, Brittany G. Craiglow, Feng Dai, Brett A. King
- Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study
- Robert Bissonnette, Yves Poulin, Janice Drew, Hans Hofland, Jerry Tan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?